410 related articles for article (PubMed ID: 25393216)
1. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
2. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
3. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
4. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
6. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
[TBL] [Abstract][Full Text] [Related]
7. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
8. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
[TBL] [Abstract][Full Text] [Related]
9. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
Vosburg SK; Haynes C; Besharat A; Green JL
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
[TBL] [Abstract][Full Text] [Related]
10. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.
Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS
Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238
[TBL] [Abstract][Full Text] [Related]
11. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
12. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.
Wolff C; Dowd WN; Ali MM; McClellan C; Meinhofer A; Glos L; Mutter R; Rosenberg M; Schick A
Addict Behav; 2020 Jun; 105():106268. PubMed ID: 32036188
[TBL] [Abstract][Full Text] [Related]
13. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
[TBL] [Abstract][Full Text] [Related]
14. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
15. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
[TBL] [Abstract][Full Text] [Related]
17. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
[TBL] [Abstract][Full Text] [Related]
18. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
19. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
20. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
